CA2196671A1 - Deuterium-containing pharmaceutical compositions for destroying tumors - Google Patents

Deuterium-containing pharmaceutical compositions for destroying tumors

Info

Publication number
CA2196671A1
CA2196671A1 CA 2196671 CA2196671A CA2196671A1 CA 2196671 A1 CA2196671 A1 CA 2196671A1 CA 2196671 CA2196671 CA 2196671 CA 2196671 A CA2196671 A CA 2196671A CA 2196671 A1 CA2196671 A1 CA 2196671A1
Authority
CA
Canada
Prior art keywords
deuterium
carcinomas
cells
pharmaceutical composition
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2196671
Other languages
English (en)
French (fr)
Inventor
Albrecht Bauer
Axel Haase
Ulrich Bogdahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2196671A1 publication Critical patent/CA2196671A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2196671 1994-08-04 1995-08-03 Deuterium-containing pharmaceutical compositions for destroying tumors Abandoned CA2196671A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19944427690 DE4427690A1 (de) 1994-08-04 1994-08-04 Deuterium enthaltende pharmazeutische Zusammensetzung als Zytostatikum oder Tumor-Therapeutikum
DEP4427690.7 1994-08-04

Publications (1)

Publication Number Publication Date
CA2196671A1 true CA2196671A1 (en) 1996-02-15

Family

ID=6524964

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2196671 Abandoned CA2196671A1 (en) 1994-08-04 1995-08-03 Deuterium-containing pharmaceutical compositions for destroying tumors

Country Status (5)

Country Link
EP (1) EP0773784A1 (de)
AU (1) AU3257095A (de)
CA (1) CA2196671A1 (de)
DE (1) DE4427690A1 (de)
WO (1) WO1996003996A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2083210C1 (ru) * 1995-09-13 1997-07-10 Николаева Ирина Сергеевна Средство для профилактической, поддерживающей и восстановительной терапии развивающихся при старении и/или под воздействием патогенных факторов патологий, связанных с дистрофическим и дегенеративными изменениями органов и тканей
RO121676B1 (ro) * 2004-08-18 2008-02-28 Institutul Oncologic "Prof.Dr. Al. Trestioreanu" Metodă de creştere a toleranţei organismului la tratamentul cu citostatice
US7601737B2 (en) 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
DE102006049185A1 (de) * 2006-10-18 2008-04-24 Bayerl, Thomas M., Prof. Dr. Verwendung von Deuteriumdioxid zur Behandlung von hyperproliferativen Erkrankungen der Haut
DE102007031397A1 (de) * 2007-07-05 2009-01-08 D2O Bioscience Group Ltd. Verwendung von Deuteriumoxid zur Behandlung von Virus-basierten Erkrankungen der Haut
EP2110132B1 (de) 2008-04-20 2014-01-22 D2 Bioscience Group Ltd Verwendung von Deuteriumoxid als Elastase-Inhibitor
DE102009003942A1 (de) 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
CN105311051A (zh) 2014-05-26 2016-02-10 陈松源 具有增加抗肿瘤药物疗效的载体溶媒、制备方法及其给药途径

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002663A (en) * 1975-03-03 1977-01-11 G. D. Searle & Co. Deuterated prostaglandin analogs
US4529600A (en) * 1982-09-09 1985-07-16 Sri International Pentadeuterioretinoids
JPS60152487A (ja) * 1984-01-18 1985-08-10 Sato Yakugaku Kenkyusho:Kk デユウテロポルフイリン誘導体及びその塩
GB8705780D0 (en) * 1987-03-11 1987-04-15 Norsk Hydro As Anticancer compounds
GB2208798B (en) * 1987-07-20 1991-06-05 Norsk Hydro As Anti-cancer agent comprising l-ascorbic acid and o-benzylidene-l-ascorbic acid or deuterated derivative
GB8726505D0 (en) * 1987-11-12 1987-12-16 Ici Plc Naphtho(2 1-b)furan derivatives
GB8810173D0 (en) * 1988-04-29 1988-06-02 Norsk Hydro As Pharmaceutical compositions with anti-cancer activity & method for treatment of cancer
US5032610A (en) * 1988-11-21 1991-07-16 Norsk Hydro As Activity against carcinoma and method for the treatment of carcinoma
US5135948A (en) * 1988-11-21 1992-08-04 Norsk Hydro A.S. Pharmaceutical compositions with anti-cancer activity against carcinoma and method for the treatment of carcinoma
HU208084B (en) * 1991-10-31 1993-08-30 Hyd Kutato Fejlesztoe Kft Process for producing compositions suitable for curing tumorous diseases
GB9201275D0 (en) * 1992-01-21 1992-03-11 Norsk Hydro As New compounds
GB9214202D0 (en) * 1992-07-03 1992-08-12 Leo Pharm Prod Ltd Chemical compounds
NO940195L (no) * 1993-01-25 1994-07-26 Norsk Hydro As Nye forbindelser
US5382582A (en) * 1993-03-26 1995-01-17 Chan; Carcy L. Methotrexate analogs and methods of using same
DE4343838C2 (de) * 1993-12-22 1998-07-09 Lohmann Therapie Syst Lts Deuteriertes Arzneimittel in transdermaler Applikation und Verfahren zu seiner Herstellung
GB9400047D0 (en) * 1994-01-04 1994-03-02 Norsk Hydro As Pharmaceutical compositions

Also Published As

Publication number Publication date
EP0773784A1 (de) 1997-05-21
DE4427690A1 (de) 1996-02-08
AU3257095A (en) 1996-03-04
WO1996003996A1 (de) 1996-02-15

Similar Documents

Publication Publication Date Title
Casciari et al. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours
Pinedo et al. Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity
Cruz et al. In vitro and in vivo antineoplastic effects of ortrovanadate
CA2196671A1 (en) Deuterium-containing pharmaceutical compositions for destroying tumors
Olah et al. Phase and cell cycle specificity of pyrazofurin action
US20090264382A1 (en) Methods for Treating Hematopoietic Neoplasms
Osmak et al. Ascorbic acid and 6-deoxy-6-chloro-ascorbic acid: potential anticancer drugs
Cunningham et al. 5-Fluorouracil and folinic acid: a phase I–II trial in gastrointestinal malignancy
Kido et al. Increased cytotoxicity of low-dose, long-duration exposure to 5-fluorouracil of V-79 cells with hyperthermia
Teicher et al. Interaction of tomudex with radiation in vitro and in vivo.
Scheithauer et al. Treatment of patients with advanced colorectal cancer with cisplatin, 5‐fluorouracil, and leucovorin
Dosik et al. Lethal and cytokinetic effects of anguidine on a human colon cancer cell line
Marx et al. Treatment of hamster pancreatic cancer with α-difluoromethylornithine, an inhibitor of polyamine biosynthesis
Kano et al. Effects of nitrous oxide on human cell lines
Vietti et al. Kinetics of Cytotoxicity of VM-26 and VP-16-213 on L1210 Leukemia and Hematopoietic Stem Cells 1, 2
Mickey et al. Conventional chemotherapeutic agents combined with DMSO or DFMO in treatment of rat prostate carcinoma
Traganos et al. Effects of dihydro-5-azacytidine on cell survival and cell cycle progression of cultured mammalian cells
Boughattas et al. Modulation of cisplatin chronotoxicity related to reduced glutathione in mice
Silvestrini et al. Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells
Muriel et al. Dose-response studies of interferon-α2b on liver fibrosis and cholestasis induced by biliary obstruction in rats
Edmonson et al. Phase I Study of Difluoromethylornithine in Combination with Recombinant α2a-Interferon
Vogl et al. Sequential methotrexate and 5‐fluorouracil with bleomycin and cisplatin in the chemotherapy of advanced squamous cancer of the head and neck
Bor et al. Phosphoprotein B23 translocation and modulation of actinomycin D and doxorubicin cytotoxicity by dipyridamole in HeLa cells
Ajani et al. Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma
Buroker et al. Phase II trial of ftorafur with mitomycin C. versus ftorafur with methyl CCNU in untreated colorectal cancer

Legal Events

Date Code Title Description
FZDE Dead